Nitazoxanide as a new local adjunctive to nonsurgical treatment of stage II periodontitis: Clinical and Biochemical evaluation | ||||
Egyptian Dental Journal | ||||
Article 12, Volume 68, Issue 1 - Serial Number 3, January 2022, Page 457-466 PDF (613.4 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/edj.2021.103287.1843 | ||||
![]() | ||||
Authors | ||||
Maha R Taalab ![]() | ||||
1Oral Medicine,Periodontology,Diagnosis and Radiology department, Faculty of Dentistry,Alexandria University | ||||
2Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt | ||||
3Department of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Alexandria University, Egypt | ||||
4Department of Oral Medicine, Periodontology, Oral Diagnosis and Oral Radiology department. Faculty of Dentistry, Alexandria University, Alexandria, Egypt. | ||||
Abstract | ||||
ABSTRACT Objectives: In this study the effect of Nitazoxanide (NTZ) delivered subgingivally as thermosensitive hydrogel on the clinical and biochemical outcomes of scaling and root planing (SRP) was evaluated compared to SRP alone in patients with stage II periodontitis. Materials and Methods: A randomized, controlled clinical trial was conducted on forty adult patients equally divided between a control group treated with full-mouth SRP and a test group treated with SRP and sub gingivally-delivered 0.01% NTZ gel. The gel was administered twice, one week after SRP and a week later. Probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI), and matrix metalloproteinase-8 (MMP-8) levels in gingival crevicular fluid (GCF) were measured at baseline and after 3 and 6 months and compared in addition to the reduction in these values from baseline to 6 months using Mann-Whitney U test. Results: There were significantly greater reductions in the test than the control groups at 6 months regarding PD (mean= 3.1mm and 2.3mm, P= 0.001), CAL (2.3mm and 1.7mm, P= 0.013), percentage of sites with BoP (mean= 1.6% and 1%, P= 0.001), GI (mean= 2.3 and 1.6, P= 0.006), and MMP-8 level (mean= 1.8 and 0.9, P= 0.028). Conclusions: NTZ has potential when combined with SRP as an adjunctive for the treatment of stage II periodontitis, offering added benefit over SRP alone based on clinical and biochemical findings. Trial registration: The study was retrospectively registered at clinicaltrials.gov, NCT04768530 on 24/2/2021. Keywords: Antimicrobial, Biochemical, Gingival crevicular fluid, Matrix metalloproteinase-8, Periodontitis. | ||||
Keywords | ||||
Antimicrobial; Biochemical; Gingival crevicular fluid; Matrix metalloproteinase-8; Periodontitis | ||||
Statistics Article View: 435 PDF Download: 323 |
||||